Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
Journal of the European Academy of Dermatology and Venereology | May 23, 2018
Most read this week